Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Acta Neurológica Colombiana
Print version ISSN 0120-8748
Abstract
CASALLAS VANEGAS, Adriana; ZULUAGA RODAS, Maria Isabel and REYES GUERRERO, Marco Aurelio. Clinically isolated syndrome: approach to the first demyelinating event. Acta Neurol Colomb. [online]. 2019, vol.35, n.2, pp.64-73. ISSN 0120-8748. https://doi.org/10.22379/24224022236.
Clinically Isolated Syndrome (CIS), denotes the first neurological symptom suggestive of Multiple Sclerosis (MS), at least 24 hours in duration; In the absence of fever, infectious processes and encephalopathy. It is characterized by its frequent presentation in young adults and affects the optic nerve, brainstem or spinal cord. The early stratification of CIS is essential because with clinical, radiological and biological predictors, the risk of conversion to MS can be established. The use of Disease Modifying Therapies (DMT) in CIS has been shown to delay the conversion of CIS to Multiple Sclerosis by 44 to 50 %%. However, not all patients with CIS will evolve to MS, so the study of several prognostic markers will allow to recognize the ideal scenario where patients benefit from the early onset of DMT.
Keywords : Demyelinating Diseases; Oligoclonal bands; Multiple Sclerosis; Magnetic Resonance; Cerebroespinal Fluid; Drug therapy (MeSH).